Compare GORO & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GORO | RFL |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Real Estate |
| Sector | Basic Materials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 61.1M |
| IPO Year | 2010 | 2017 |
| Metric | GORO | RFL |
|---|---|---|
| Price | $1.32 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.75 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 92.9K |
| Earning Date | 04-16-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | N/A |
| Revenue | ★ $65,726,000.00 | $917,000.00 |
| Revenue This Year | $9.04 | N/A |
| Revenue Next Year | $93.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.34 | $1.12 |
| 52 Week High | $1.87 | $3.19 |
| Indicator | GORO | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 48.08 |
| Support Level | $1.27 | $1.15 |
| Resistance Level | $1.75 | $1.38 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 1.75 | 30.00 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.